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Abstract 
Background: Human myxovirus resistant protein A (MxA), encoded by the myxovirus resistance 1 (Mx1) gene, is 
an interferon (IFN)‑triggered dynamin‑like multi‑domain GTPase involved in innate immune responses against viral 
infections. Recent studies suggest that MxA is associated with several human cancers and may be a tumor suppressor 
and a promising biomarker for IFN therapy. Mx1 gene mutations in the coding region for MxA have been discovered 
in many types of cancer, suggesting potential biological associations between mutations in MxA protein and cor‑
responding cancers. In this study, we performed a systematic analysis based on the crystal structures of MxA and 
elucidated how these mutations specifically affect the structure and therefore the function of MxA protein.
Methods: Cancer‑associated Mx1 mutations were collected and screened from the COSMIC database. Twenty‑two 
unique mutations that cause single amino acid alterations in the MxA protein were chosen for the analysis. Amino 
acid sequence alignment was performed using Clustal W to check the conservation level of mutation sites in Mx 
proteins and dynamins. Structural analysis of the mutants was carried out with Coot. Structural models of selected 
mutants were generated by the SWISS‑MODEL server for comparison with the corresponding non‑mutated struc‑
tures. All structural figures were generated using PyMOL.
Results: We analyzed the conservation level of the single‑point mutation sites and mapped them on different 
domains of MxA. Through individual structural analysis, we found that some mutations severely affect the stability 
and function of MxA either by disrupting the intra‑/inter‑molecular interactions supported by the original residues or 
by incurring unfavorable configuration alterations, whereas other mutations lead to gentle or no interference to the 
protein stability and function because of positions or polarity features. The potential clinical value of the mutations 
that lead to drastic influence on MxA protein is also assessed.
Conclusions: Among all of the reported tumor‑associated single‑point mutations, seven of them notably affect the 
structure and function of MxA and therefore deserve more attention with respect to potential clinical applications. 
Our research provides an example for systematic analysis and consequence evaluation of single‑point mutations on a 
given cancer‑related protein.
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Background
The myxovirus resistance 1 (Mx1) gene is one of the most 
prominent interferon (IFN)-stimulated genes in verte-
brate that are highly activated when triggered by type I 
and III IFNs upon viral infection. Human Mx1 is located 
on chromosome 21 and encodes the myxovirus resist-
ant protein A (MxA) protein, which is a major antiviral 
factor against a wide spectrum of RNA viruses, such as 
influenza virus and Thogotovirus [1, 2]. The 78-kDa MxA 
protein is a member of the dynamin superfamily of multi-
domain GTPases whose function relies on oligomeri-
zation and GTP hydrolysis [3]. MxA has an N-terminal 
GTPase (G) domain, a stalk region responsible for oli-
gomerization, a bundle-signaling-element domain (BSE) 
crucial for the communication between the G domain 
and the stalk region [4–6], and a 40-amino-acid-long 
loop (conventionally named L4) amid the Stalk on pri-
mary structure correlated with the pleckstrin homology 
(PH) domain in dynamin [3]. Besides, MxA possesses a 
disordered loop at the N-terminus that is not conserved 
within the dynamin superfamily. According to the cur-
rent working model, MxA forms ring-like oligomers 
around viral ribonucleoparticles (RNPs) and disrupts the 
structure of RNPs via conformational changes induced by 
GTP hydrolysis [5].
Apart from its role as a prominent antiviral protein 
in innate immunity, MxA has been found to be associ-
ated with different types of human cancer. It has been 
reported that the deletion of Mx1 gene, as a consequence 
of certain gene fusion events, is closely related to prostate 
cancer with a high aggressive tendency [7]. Other studies 
of prostate cancer have suggested that the expression of 
MxA is suppressed in the highly metastatic human pros-
tate carcinoma cell line PC-3M, and exogenous MxA can 
inhibit the mobility and invasiveness of PC-3M cells both 
in vivo and in vitro [8]. Prostate cancer cells in which the 
Mx1 gene is knocked out have been shown to be much 
less sensitive to docetaxel compared with MxA-positive 
cells [9]. The Mx1 gene has been found to be hyper-
methylated and suppressed in primary head and neck 
squamous cell carcinoma cell lines and tissue samples 
compared with normal lymphocytes [10]. These studies 
indicate that Mx1 is a potential tumor suppressor gene. 
On the other hand, as a traditional immunotherapeutic 
reagent [11], type I IFNs are widely used in clinical treat-
ments against a number of human cancers, including 
renal cell carcinoma, follicular lymphoma, melanoma, 
and chronic myelogenous leukemia [12]. The effect of 
type III IFNs against different human cancers, includ-
ing bladder carcinoma, Burkitt’s lymphoma, colorectal 
carcinoma, non-small cell lung cancer, and esophageal 
carcinoma, has also been investigated [13, 14]. As a key 
cytokine induced by types I and III IFNs, MxA is thought 
to be a useful biomarker for monitoring IFN activity and 
predicting clinical efficacy during IFN therapy in patients 
bearing certain types of cancer [15, 16]. A clinical study 
on early stage B cell chronic lymphocytic leukemia has 
suggested that patients with no MxA expression are likely 
to demonstrate a positive response to IFN therapy [16]. 
Moreover, the expression level of MxA is also employed 
to predict the efficacy of chemotherapy on several types 
of cancer. A worldwide multi-center study has indicated 
that robust MxA expression is a positive indicator for 
patients with breast carcinoma who might benefit from 
anthracycline-based chemotherapy [17].
In recent years, with the development of next-gen-
eration sequencing technique and its wide application 
in cancer studies [18], the landscape of somatic muta-
tions has been revealed for many types of human cancer. 
According to these comprehensive data sets, Mx1 muta-
tions have been discovered in a number of common can-
cer types, including colorectal cancer [19–22], head and 
neck squamous cell carcinoma [23], follicular lymphoma 
[24], cutaneous squamous cell carcinoma [25], man-
tle cell lymphoma [26], embryonal rhabdomyosarcoma 
[27], renal cell carcinoma [28], prostate cancer [29], lung 
adenocarcinoma [30], melanoma [31], medulloblastoma 
[32], and ovarian carcinoma [33]. Given the potential 
importance of MxA in tumorigenesis and metastasis as 
well as in the treatment and prognosis of different can-
cers, additional efforts are needed to investigate the bio-
logical associations between Mx1 mutations, especially 
the mutations that lead to the malfunction of its encoded 
protein MxA, and corresponding cancers. Mutations in 
coding regions can result in different consequences to 
the translated polypeptides, of which single amino acid 
alterations take up a considerable portion. These single-
point mutations may give rise to various consequences 
to the function of MxA which, however, are difficult to 
be predicted and evaluated from the analysis of primary 
structure. In this study, we exploit the crystal structures 
of MxA and illustrate how these mutations specifically 
affect the structure and thus the function of MxA protein.
Methods
Data mining
Information on cancer-related mutations in human Mx1 
gene was collected from the Catalogue of Somatic Muta-
tions in Cancer (COSMIC) database [34]. All mutations 
were manually screened and only the mutations that 
cause single amino acid alterations in MxA were chosen 
for subsequent analysis.
Sequence alignment
Amino acid sequences of Homo sapiens (hs) MxA (Uni-
Prot code P20591) and MxB (P20592), Mus musculus 
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(mm) Mx1 (P09922) and Mx2 (Q9WVP9), Gallus gal-
lus (gg) Mx protein (Q90597), Danio rerio (dr) MxA 
protein (Q8JH68), Homo sapiens dynamin1 (Q05193), 
dynamin2 (P50570), and dynamin3 (Q9UQ16), Drosoph-
ila melanogaster (dm) dynamin (P27619), Caenorhabditis 
elegans (ce) dynamin (Q9U9I9), and Saccharomyces cere-
visiae (sc) dynamin-related protein DNM1 (P54861) were 
aligned using Clustal W [35] and manually adjusted for 
non-conserved loop regions.
Structural analysis
Crystal structures of full-length MxA (PDB code 3SZR), 
MxA Stalk (3LJB), apo MxA G domain-BSE fusion con-
struct (Stalkless MxA) (4P4U), and Stalkless MxA com-
plexed with β,γ-methyleneguanosine 5′-triphosphate 
(GMPPCP, a non-hydrolysable GTP analogue) (4P4S) 
were used as reference structures. For optimal accu-
racy, the resolution was considered a prior factor during 
the selection of reference structures comprising corre-
sponding mutated residues. For mutations within the G 
domain, the crystal structure of apo Stalkless MxA (1.9 
Å resolution) was applied as reference with the exception 
of L95P and P96S on Switch I. For these two mutations, 
the GMPPCP-bound Stalkless MxA structure (3.3 Å) was 
taken as reference because only when a GTP analogue is 
bound to the G domain can Switch I be ordered and fully 
observable. For mutations in the stalk region, the MxA 
Stalk structure (2.4  Å) was used for structural analysis. 
For mutations in BSE and Hinge 1, the full-length MxA 
structure (3.5 Å) was the only choice because other pub-
lished structural models do not contain these residues. 
Structural analysis for all mutations was performed using 
Coot [36]. Interactions among the residues were defined 
by the linear distance between the centers of the cor-
responding atoms in the reference models: 2.7–3.5  Å 
for hydrogen bonds and within 4 Å for salt bridges and 
hydrophobic interactions. Overall, all reference models 
provided sufficient information needed for reliable struc-
tural analysis.
Structural modeling of the mutants
Structural models of selected cancer-associated single-
point mutants were calculated by the SWISS-MODEL 
server [37]. In the amino acid sequence input files for 
each MxA mutant, the original residue was substituted 
by the post-mutation residue. Mutated MxA sequences 
were then individually uploaded to the SWISS-MODEL 
server for model calculation. The templates used for 
structural model building were assigned according to 
the corresponding reference models for each mutant as 
previously mentioned. In the output models, the residues 
that were absent in the original templates were removed 
for better quality because these parts may contain severe 
errors as a result of lacking reference information. The 
final structural models of the mutants were individually 
superimposed on the corresponding original reference 
models using Coot, and the root mean square deviation 
(r. m. s. d.) values for steric positions of the correspond-
ing atoms between each model pairs were subsequently 
calculated.
Structural figure preparation
All structural figures were generated using PyMOL [38]. 
Different types of atoms in stick or sphere representa-
tions were specified by the following colors: red for oxy-
gen, blue for nitrogen, magenta for phosphorous, light 
green for magnesium, green for sulfur, yellow for carbon 
in residues that are mutated in human cancers, and gray 
for carbon in other amino acids that interact with resi-
dues of interest in this study. The spheres in the illustra-
tion represented Cα of the corresponding residues.
Results
Overview of single‑point mutations in MxA in different 
types of cancer
In the COSMIC database, 122 tumor-related mutations 
were identified in the human Mx1 gene from whole-
genome, whole-exome, and transcriptome sequencing 
data of human cancers. All 122 mutations reside in cod-
ing regions of the MxA protein. For these genetic aber-
rances, frameshift mutations and termination codon 
mutations were excluded, as they lead to obvious trunca-
tion of the polypeptide chain and therefore the oblitera-
tion of MxA structure and function. In addition, silent 
mutations were also excluded because the amino acid 
sequence of MxA remains intact in these cases. Con-
sequently, 22 unique cancer-related single amino acid 
mutations in MxA protein were selected and subjected 
to subsequent analysis. These 22 MxA mutations, sum-
marized in Table 1, were found across 12 types of human 
cancer, of which colorectal cancer accounted for half of 
the mutations, followed by cutaneous squamous cell 
carcinoma (3 mutations) and mantle cell lymphoma (2 
mutations). The other 9 cancers each featured 1 muta-
tion. Two mutations, namely T651M and R655C, both 
appeared twice. T651M was found in colorectal cancer 
and head and neck squamous cell carcinoma, whereas 
R655C was discovered in two separate sequencing pro-
jects for colorectal cancer. Overall, MxA single-point 
mutations are widely spread in different human cancers, 
and MxA mutates more frequently in colorectal cancer 
according to current data.
We then checked the conservation level of the amino 
acid residues mutated in cancers. Seven residues are 
highly conserved in Mx proteins and dynamins; 4 resi-
dues also show considerable overall conservation. In 
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addition, 5 residues are conserved in Mx proteins but not 
in dynamins, whereas 6 residues display no conservations 
at all (Fig. 1). Intriguingly, T651 and R655, although their 
corresponding mutations appeared more frequently in 
sequencing data, belong to non-conserved group. This 
result suggests that it is obscure to infer the physiologi-
cal importance of these single-point mutations only from 
their conservativeness in primary structure. To obtain 
more reliable information, individual analysis of these 
mutations by structural means is indispensable.
Distribution of cancer‑related single‑point mutations 
in MxA
Human MxA protein is a large dynamin-like GTPase 
composed of 5 structurally discriminated domains plus 
an N′-loop (Fig. 2a). Recently, several crystal structures of 
MxA have been reported, which collectively covered most 
of the molecule, except for the N′-loop and L4 [4–6]. We 
took advantage of these structures to perform an in-depth 
analysis of the 22 cancer-related mutations and their pos-
sible structural and functional outcomes on the protein. 
First, we mapped the mutated residues on MxA molecule 
and found that these 22 mutations are scattered through-
out all regions (Fig. 2b). The G domain, which is largest in 
size, contains 7 mutation sites, whereas the smaller N′-loop 
and Hinge 1 each contains 1 mutation site. Considering 
the size, however, BSE and L4 are relatively more prone to 
mutation, where 5 and 3 mutation sites are spotted, respec-
tively (Fig. 2c–f). The distribution of the mutations is sum-
marized in Table  2. Next, all single-point mutations were 
individually investigated according to the domains.
Single‑point mutations in G domain
The G domain of MxA is responsible for GTP hydroly-
sis, as well as for the inter-ring homo-dimerization via 
the nucleotide-binding pocket [39]. Both actions are cru-
cial for the mechano-chemical coupling of the entire oli-
gomer and thus for the function of the protein [5, 6].
Cutaneous squamous cell carcinoma-associated sin-
gle-point mutations L95P and P96S sit within Switch I, a 
key component of the active site which harbors guanine 
nucleotides and exists in all known GTPases [40]. L95 is 
deeply buried in a comprehensive hydrophobic pocket 
composed of L87, V93, L107, L109, I143, and L164 
(Fig.  3a). Its mutation to proline is less favored in this 
hydrophobic network and thereby affecting the stability 
of the whole domain. Besides, as proline and glycine are 
chemically different from other amino acids in ψ and ϕ 
dihedral angles about the peptide bond, L95P mutation 
may lead Switch I to a different bending direction, and 
this will hinder the binding of nucleotides (Fig. 3b). Simi-
larly, P96S mutation tends to generate more freedom for 
Switch I to swing, which is also unfavorable for nucleo-
tide binding and hydrolysis (Fig. 3b).
S134L mutation occurs between the extra β-strand 1 
(βE1G) and extra α-helix (αEG) of MxA (Fig. 3c). As the 
polar S134 is located on the surface of the molecule, and 
its side chain also protrudes outward, its mutation to 
hydrophobic leucine would not influence the global fold-
ing of the G domain, but just slightly change the surface 
entropy of the molecule.
P218S mutation emerges between β-strand 4 (β4G) and 
α-helix 3 of the G domain (α3G). P218 terminates β4G 
and turns the polypeptide chain to the opposite direction 
Table 1 Summary of reported human myxovirus resistant 
protein A (MxA) single-point mutations in human cancers
a R655C mutation was discovered in colorectal cancer in two individual 
sequencing projects
Cancer type Mutation(s)
Colorectal cancer S134L, N491K, R522C, T651M, 
R654Q, V263M, Y538C, 
S572Y, R655C (2)a
Head and neck squamous cell carcinoma T651M
Follicular lymphoma T27S
Cutaneous squamous cell carcinoma L95P, P96S, P218S
Mantle cell lymphoma G540D, L643V
Embryonal rhabdomyosarcoma V449G






(See figure on next page.) 
Fig. 1 Amino acid sequence alignment of myxovirus resistance (Mx) proteins and dynamins. Amino acid sequences of Mx proteins and dynamins 
from human, mouse, chicken, zebra fish, fruit fly, C. elegans, and yeast are shown in the sequence alignment (see the “Methods” for details). Residues 
with a conservation of greater than 70% are color-coded (negatively charged amino acid residues D and E in red; positively charged R, K, and H in 
blue; polar N, Q, S, and T in grey; weak or nonpolar A, L, I, V, F, Y, W, M, and C in green; and special P and G in brown). Numbers in square brackets in front 
of each 10‑residue sequence fragment indicate the ordinal position of the first residue of this fragment at the primary structure of the correspond‑
ing protein. Tumor‑associated mutations are indicated at the corresponding positions. Residues highly conserved in Mx proteins and dynamins 
(L95, P96, P218, V263, L619, E632, and L643) are shown in violet, residues showing considerable overall conservation (S134, R310, G392, and Y538) in 
magenta, residues conserved in Mx proteins but not in dynamins (K326, V449, S572, R649, and R654) in yellow, and residues with no conservative‑
ness (T27, N491, R522, G540, T651, and R655) in cyan
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(Fig. 3d). Analogous to P96S, P218S may change the orig-
inal trajectory of the following loop and therefore affect 
the folding of the protein.
V263 is surrounded by several other hydrophobic resi-
dues, including I223, L246, V264, and V268 (Fig.  3e). 
Compared with the hydrophobic pocket engulfing L95, 
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the hydrophobic environment around V263 is much 
less extensive. As methionine is also a nonpolar residue, 
V263M mutation makes no alteration of the hydrophobic 
property of this area. Although methionine is physically 
a bulkier residue than valine, there is enough space at the 
top of V263 to accommodate a methionine side chain. 
Therefore, V263M mutation would cause very limited 
influence to the folding and stability of the protein.
R310 sits on the surface of the molecule. The side chain 
of R310 points outward and is quite flexible, as two con-
formations can be observed in the crystal structure, 
Fig. 2 Overview of the distribution of cancer‑related mutations 
within the human myxovirus resistant protein A (MxA) domains. a 
schematic representation of the domain structure of human MxA. 
N′-loop N‑terminal disordered loop; B bundle‑signaling‑element 
domain (BSE), G G domain; H Hinge 1, S Stalk. Borders of the domains 
are indicated by corresponding residue numbers. b overview of 
the position of all mutations in MxA. The G domain is colored in 
orange, BSE in red, Hinge 1 in sky-blue, and Stalk in green. The missing 
N‑terminal 44 residues (shown in magenta) and L4 (shown in cyan) 
are indicated as dashed lines. Mutations that are included by the refer‑
ence model are illustrated as yellow spheres. Residues that are missing 
in this reference model but are present in other reference models 
are illustrated as filled yellow circles. Residues missing in all reference 
structures are shown as yellow stars. c–f overview of the mutations in 
individual domains of MxA, as outlined by dashed rectangles in Fig. 2a 
at the corresponding areas: c G domain, d BSE, e Hinge 1, and f Stalk. 
Note that the representations of e Hinge 1 and f Stalk representations 
were rotated counter‑clockwise 90° from those in Fig. 2b
Table 2 Domain distribution of cancer-related MxA single-
point mutations
MxA segment Mutation(s) in cancers




L643V, R649W, T651M, R654Q, 
R655C
Stalk G392V, V449G, N491K, R522C, L619I
Hinge 1 E632K
L4 G540D, Y538C, S572Y
N′‑loop T27S
Fig. 3 Cancer‑related MxA mutations in G domain. a L95 is deeply 
buried in a hydrophobic cave. b P96 leads the direction of Switch I, 
which embraces guanine triphosphate nucleotide. c S134 is located 
on the surface of the G domain. d P218 sits at the end of β‑strand 
4 (β4G). e V263 is loosely enwrapped by neighboring hydrophobic 
residues. f R310 is exposed to the solvent and takes two side chain 
conformations, whereas K326N interacts with vicinal residues. All 
cancer‑related mutations are shown as the original (i.e., non‑mutated) 
residues, and the post‑mutation residues are included in the labels, as 
L(original)95P(post‑mutation), and so on. This scheme is also applied 
to all of the following figures
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which suggests that this residue is not bound by any 
side-chain interaction from other parts of the protein 
(Fig. 3f ). In this situation, its mutation to a polar serine 
residue will neither break any intra-molecular associa-
tions nor drastically change the surface polarity of MxA. 
Although R310S causes the loss of some positive charge, 
this mutation would not negatively affect the function of 
the protein.
K326 is located in α-helix 5 of the G domain (α5G) and 
also has an outward side-chain conformation. It forms a 
hydrogen bond with the oxygen of K273 and addition-
ally a weak salt bridge with E330 which also sits in α5G 
(Fig.  3f ). The K326  N mutation may not substantially 
affect these two interactions, as asparagine also has a 
polar side chain that can form hydrogen bonds with 
K273 and E330. Therefore, it is very likely that this muta-
tion does not give rise to any major disruptions of MxA 
structure.
Single‑point mutations in BSE
The BSE is composed of three α-helices which are widely 
dispersed at the very N-terminus, middle, and the very 
C-terminus of MxA protein, respectively [5]. BSE is 
the pivot for transmitting the mechanical force gener-
ated from GTP hydrolysis at the G domain to the stalk 
region, so as to regulate Stalk-dependent oligomerization 
of the molecule [41]. Five tumor-associated single-point 
mutations were found in BSE and, more precisely, the 
α-helix 3 of BSE (α3B), which is also close to the end of 
the protein (Fig. 4a). According to the crystal structure of 
full-length MxA, all these 5 residues exhibit an outward 
side chain conformation. L643 is hydrophobically linked 
to L357, but its mutation to nonpolar valine would not 
substantially disrupt this interaction, and thus does not 
adversely affect the structure of the protein. The side 
chains of R649, T651, and R655 are all located within a 
spacious environment and have no contact to other ele-
ments of the molecule. Therefore, their mutations, except 
for mutating to glycine or proline, will lead to negligi-
ble interference in the folding of the protein. However, 
since arginine and threonine are both strong polar resi-
dues, whereas methionine and tryptophan possess bulky 
hydrophobic side chains, and cysteine is a weak-polar 
residue prone to various post-translational modifica-
tions, the R649W, T651M, and R655C mutations bear 
the possibility to interrupt the association between the 
protein and other protein partners or incur unexpected 
modifications.
In addition to its role as an intra-molecular mes-
senger, BSE also contributes to the formation of func-
tional homo-oligomers, which is a fundamental feature 
of dynamin superfamily members (Fig.  4b). R654 par-
ticipates in BSE-Stalk interaction between parallel MxA 
monomers via a charged interaction with D478 on the 
other molecule (Fig. 4c). Disruption of this salt bridge by 
a D478A mutation results in abnormal GTPase activity 
and weakened oligomerization and antiviral abilities [4]. 
Not surprisingly, the colorectal cancer-associated R654Q 
mutation, which abolishes the D478-R654 salt bridge, 
should have a similar effect. On the other hand, glu-
tamine still possesses the tendency to form a hydrogen 
bond with D478, and this can be deemed as a compensa-
tion for the loss of the salt bridge. As a result, this mutant 
would hardly cause negative consequence to MxA com-
pared with the reported D478 mutant.
Single‑point mutation in Hinge 1
Hinge 1 plays a crucial role in connecting BSE and the 
stalk region. Extensive interactions between the two 
loops of Hinge 1 (L1H and L2H) stabilize the ambient 
region so that the relative position of BSE and Stalk is 
confined from random movement [4]. The salt bridge 
formed by E632 on L1H and R640 on α3B is the deter-
mining factor in this stabilization effect (Fig. 5). Destruc-
tion of this salt bridge by mutating either E632 or R640 
to alanine leads to tremendous change of GTPase activ-
ity, and almost completely abolishes the oligomerization 
ability and antiviral effect of MxA. Therefore, it can be 
well expected that the melanoma-related mutant E632K, 
which also disrupts the E632-R640 interaction, would 
be detrimental to the integrity of Hinge 1, and thus the 
global stability of MxA molecule.
Fig. 4 Cancer‑related MxA mutations in BSE. a surface‑located muta‑
tions and a surrounding residue. b the full‑length MxA oligomer in 
the crystal lattice represented by a linear hexamer. All 6 monomers 
are distinguished by 6 different colors and indicted by corresponding 
numbers. c A magnified view from the dashed rectangle in Fig. 4b 
shows that the R654 is involved in inter‑molecular Stalk‑BSE interac‑
tion
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Single‑point mutations in the stalk region
The stalk region is essential for the functional assem-
bly of dynamin superfamily members including MxA 
[5, 42, 43]. In crystal lattice, MxA stalk was found 
forming linear oligomers via several conserved inter-
faces, which were then proven to also mediate the 
architecture of ring-like oligomers in physiological 
conditions [4] (Fig. 6a). Therefore, it was necessary to 
first determine the mutations residing in these inter-
faces, namely G392V and V449G. G392 is located on 
interface 3 and highly conserved in dynamins and Mx 
proteins (Fig.  6b). The G392D mutation in MxA was 
demonstrated to disrupt the oligomerization of the 
protein [4]. Moreover, its counterpart mutation (G385) 
in yeast dynamin leads to the breakdown of tetramer 
into stable dimers [44]. It is therefore not astonishing 
that the G392V mutation found in renal cell carcinoma 
deprives the oligomerization capability of MxA and 
thus its biological activity. In addition, the V449 resi-
due was found to be the interaction partner of G392 on 
the parallel monomer in the MxA oligomer (Fig.  6b). 
Its mutation to glycine tends to affect the integrity of 
interface 3, as well as the conformation of the subse-
quent Loop 2 on the stalk (L2S). Altogether, these two 
mutations (G392V and V449G) are likely to impair the 
physiological function of MxA.
On the other hand, three additional single-point muta-
tions that are not involved in any oligomerization inter-
faces have been discovered in the stalk region. N491 is a 
surface-located residue situated on the α-helix 2 of Stalk 
(α2S), forming a hydrogen bond with D385 on the parallel 
α-helix 1N-terminal part (α1NS) (Fig. 6c). Its mutation to 
positively charged arginine may strengthen this interac-
tion, as a salt bridge can be thus introduced. Therefore, 
this single-point mutation would play an insignificant 
role in tumorigenesis or in the development of colorec-
tal cancer [22]. Another colorectal cancer-related muta-
tion site, R522, is also a solvent-exposed residue on α3S. 
This residue, together with three neighboring negatively 
charged glutamates (E466 and E467 on α2S, and E518 
on α3S), constitutes a vast network of charged interac-
tions endorsed by the salt bridges, in which R522 is at the 
center, to provide positive charge (Fig. 6d). It is imagina-
ble that its mutation to weak polar cysteine causes the 
absence of the pivotal positive charge and lead to inter-
ference of electrostatic balance on the protein surface. In 
this case, the folding and stability of the whole protein 
would become adversely influenced. Unlike N491 and 
R522, L619 located on α4S possesses an inward side chain 
conformation. It is part of a local hydrophobic core that 
includes L498 on α3S, M616 on α4S, and L629 on α5S. 
When mutated to isoleucine, a derivative comparable 
to leucine itself in both size and charge, the residue can 
still stably reside in and maintain this environment. As a 
result, this ovarian carcinoma-associated mutation L619I 
will lead to hardly detectable structural and functional 
aberrance to MxA.
Fig. 5 Cancer‑related MxA mutations in Hinge 1. E632 in Hinge 1 
forms a salt bridge with R640 to stabilize the local conformation. Part 
of the Stalk was removed for clarity
Fig. 6 Cancer‑related MxA mutations in Stalk. a the MxA Stalk 
oligomer in the crystal lattice, as represented by a linear hexamer. 
The monomers are color-coded and labeled in the same manner as 
in Fig. 4b. Note that compared with the relative direction of the full‑
length MxA hexamer in Fig. 4b, the Stalk hexamer has been rotated 
clockwise for 90° along the X axis, and then 180° along the Y axis. b 
A magnified view from the dashed rectangle in Fig. 6a corresponding 
to interface 3 shows the interaction between G392 and V449 from 
parallel monomers. The monomers 2 and 4 are removed for clarity. 
The invisible Loop 2 on the stalk (L2S) in this model is indicated with a 
dashed line. c N491 forms a hydrogen bond with D385 from another 
α‑helix. d R522 is enveloped by three nearby glutamates. e L619 is 
surrounded by several hydrophobic residues
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Single‑point mutations in the N′‑loop and L4
The N′-loop and L4 are both intrinsically disor-
dered loops that lack intra-molecular interactions 
with other residues, and therefore, it is impractical 
to observe them in crystal structures. The N′-loop 
is not conserved among Mx proteins, and its length 
varies among different species. This region was 
recently reported to be involved in the specifica-
tion of viral targets [45]. Given the similar properties 
of threonine and serine, the T27S mutant would not 
chemically differ from wild-type MxA, but it is unpre-
dictable whether this mutation would affect the pro-
tein’s interaction with viral structures. L4 is essential 
for membrane binding and viral resistance by direct 
interaction [46, 47]. However, currently only several 
residues in the middle of L4, but not Y538, G540, or 
S572, were proven to be functionally important for 
MxA [4, 47]. Therefore, it is difficult to predict the 
influence of these three mutations on MxA function, 
although they are not likely to disrupt the flexible 
conformation of L4.
Discussion
As next-generation sequencing data of different human 
cancers continue to accumulate, abounding tumor-
associated mutations of various types are being discov-
ered and further analyzed. Compared with frame shift 
and stop codon mutations in the coding regions of given 
genes, it is more tricky to judge the effect of single amino 
acid alterations on the physiological properties of the 
proteins. In principal, functional proteins entail orches-
trated intra-molecular interactions of the component 
residues and proper folding of entire polypeptide chains, 
which can be substantiated as so-called protein struc-
tures. In regards to analyses of single-point mutations, if 
the structures of the corresponding proteins have been 
solved by X-ray crystallography or other techniques with 
a decent resolution, the prediction of the effects of these 
mutations becomes much more reliable.
When doing such predictions, one needs to take the 
following points into account: the types (or more pre-
cisely, the chemical properties) of the pre- and post-
mutation residues, the position of the residue, and the 
known inter-molecular interactions this particular 
protein accounts for. In our structural analysis of 22 
single amino acid mutations found in various human 
cancers, we scrutinized all target mutants by means of 
the above criteria and summarized the corresponding 
results in Table  3. According to our judgment of how 
severely the structure and function of MxA would be 
affected, the mutations were classified into 4 groups: 
drastic, moderate, very moderate, and unpredictable. 
For drastic mutations, most of them are relevant to 
glycine or proline. These two residues have distinct 
stereochemical features compared with the other 18 
amino acids. Proline has a confined configuration and 
usually appears at sharp turns of a peptide chain but 
seldom in α-helices and β-strands. Therefore, muta-
tions either from or to proline may mislead the pep-
tide chain to inappropriate directions and/or give rise 
to unexpected kinks in secondary structure elements. 
In contrast, glycine is the most limber residue, and 
thus mutations that involve this amino acid may alter 
the flexibility of the peptide chain at particular posi-
tions. All these outcomes are fatal to the folding of the 
protein.
According to our analysis, besides proline- and gly-
cine-related mutations, other mutations cannot be 
associated with influencing levels only by single factor 
(position or chemical properties) (Table  3). To provide 
a more intuitionistic view of how these mutations may 
affect the structure of MxA, we performed modeling of 
several mutants selected from all four groups, and com-
pared the output models to the original crystal struc-
tures. However, the calculated mutant models just bear 
tiny variations compared with the corresponding origi-
nal structures (r. m. s. d. values less than 0.1 Å). The rea-
son is that current structure prediction algorithms rely 
on the primary sequence alignment of reference struc-
tures, and differences for amino acids in stereochemis-
try and polarity are not taken into account during model 
calculation. Therefore, analyzing single-point mutations 
requires careful and comprehensive manual considera-
tions in multiple aspects involving chemical properties 
of specific amino acid residues as well as those of the 
whole protein.
The seven drastic MxA mutations found in this study 
(L95P, P96S, G392V, V449G, P218S, R522C, and E632K) 
are likely to play important roles in tumorigenesis and 
development of corresponding human cancers, and 
therefore evolve to effective tumor-related biomark-
ers, although more biochemical and cellular assays are 
needed for their potential clinical applications. Moreover, 
it is noteworthy that all three cutaneous squamous cell 
carcinoma-related mutations (L95P, P96S, and P218S) 
lead to remarkable disruption of the protein structure, 
suggesting a strong association between this cancer type 
and MxA. Finally, our systematic approaches of struc-
ture-based analysis for single-point mutations in MxA 
protein are widely applicable to the evaluation of out-
comes of mutations in different types of cancer for those 
proteins with available structural information.
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Conclusions
In this study, by analyzing 22 unique tumor-associ-
ated mutations in the human MxA protein by struc-
tural methods, we found that 7 out of 22 mutations 
have a high propensity to affect tumorigenesis and the 
development of corresponding cancers. These seven 
mutations are therefore more prone to potential clini-
cal application as useful biomarkers. In addition, our 
research provides a good example for thorough analysis 
and consequence evaluation of single-point mutations 
on a given cancer-related protein.
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